Guidelines for Use of Idarucizumab injection in UMMC

19th October 2017 (Circular NO. SP PPUM: 380/2017): Idarucizumab 2.5g (Praxbind) Injection has been approved by UMMC's Drugs & Therapeutics Sub-Committee in July 2017 as a Standard Formulary Medication in UMMC. It is a potential life-saving medication that reverses the action of the oral anti-coagulant medication, Dabigatran. Idarucizumab is meant for use in: Life-threatening / uncontrolled bleeding OR When emergency surgery / procedures are required for patients currently on Dabigatran. A Cardiology Consultant or Lecturer must be consulted for every case prior to Idarucizumab therapy. The recommended dosage is 5g (2 vials) intravenously over 10 minutes Supply of Idarucizumab is kept at Emergency Pharmacy and only TWO (2) sets of 2 vials can be made available per year due to its very high cost. Please refer to the chart below for easy referencing.